Abbott Labs: AI and Expansion Drive Health Tech Dominance

Abbott Laboratories continues to innovate at the intersection of healthcare and AI. With new coverage for its Libre sensors and AI-driven patient guidance, ABT remains a top-tier pick for consistent growth and income.

Analysis

Trading at $124.3, ABT offers a balanced 2.02% yield and a strong history of performance.

Recent Catalysts

Libre Assist: The launch of an AI-driven feature for real-time meal guidance for diabetes patients is a major step in digital health.
Global Reach: The FreeStyle Libre 3 Plus sensor just secured public funding across all Canadian provinces, significantly expanding its market.
Earnings Strength: Wall Street is bullish on Abbott’s EPS growth, with a 12.53% total shareholder return over the past year.

The company's ability to combine a 'good story' with real EPS growth makes it an interesting case for any diversified portfolio.

The Income Verdict

ABT is a 'safe and steady' play for income investors, offering both technological upside and defensive healthcare stability.

Shares Needed

478

shares of ABT

Capital Required

$59,405.94

invested in ABT

Monthly Income Goal$100.00/mo

$10/mo$1,000/mo

Passively Earning $100.00/month

With a dividend yield of 2.02%, holding 478 shares of ABT would generate $1,200.00 in annual passive income.

Disclaimer: This is not financial advice. Always do your own due diligence.